Alnylam Pharmaceuticals posted better-than-expected second-quarter revenue, fueled primarily by Amvuttra, its transthyretin amyloidosis cardiomyopathy therapy. Sales of Amvuttra more than doubled year-over-year, reaching $492 million and surpassing consensus estimates. The drug's uptake has been broad, spanning both new and stabilizer-progressing patients across academic and community settings, with about 80% coverage in priority health systems. This rapid adoption and strong commercial performance have propelled Alnylam's market capitalization above $50 billion, reflecting investor confidence in the company’s positioning in the rare disease treatment space.